Selected article for: "Î estimate and Î estimate"

Author: Rose, Liam; Graham, Laura; Koenecke, Allison; Powell, Michael; Xiong, Ruoxuan; Shen, Zhu; Kinzler, Kenneth W.; Bettegowda, Chetan; Vogelstein, Bert; Konig, Maximilian F.; Athey, Susan; Vogelstein, Joshua T.; Wagner, Todd H.
Title: The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19
  • Cord-id: 5bmcjhut
  • Document date: 2020_12_22
  • ID: 5bmcjhut
    Snippet: Effective therapies for coronavirus disease 2019 (COVID-19) are urgently needed, and preclinical data suggest alpha-1 adrenergic receptor antagonists (α(1)-AR antagonists) may be effective in reducing mortality related to hyperinflammation. Using a retrospective cohort design with patients in the Department of Veterans Affairs healthcare system, we use doubly robust regression and matching to estimate the association between use of α(1)-AR antagonists at time of hospitalization and likelihood
    Document: Effective therapies for coronavirus disease 2019 (COVID-19) are urgently needed, and preclinical data suggest alpha-1 adrenergic receptor antagonists (α(1)-AR antagonists) may be effective in reducing mortality related to hyperinflammation. Using a retrospective cohort design with patients in the Department of Veterans Affairs healthcare system, we use doubly robust regression and matching to estimate the association between use of α(1)-AR antagonists at time of hospitalization and likelihood of death due to COVID-19 during an inpatient stay. Having an active prescription for an α(1)-AR antagonist (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) at the time of admission had a significant negative association with in-hospital mortality (relative risk reduction 14%; odds ratio 0.75; 95% CI 0.66 to 0.86; p ≤ 0.001). These effects were also found in an expanded cohort of suspected COVID-19 patients, supporting the need for clinical trials.

    Search related documents:
    Co phrase search for related documents
    • active prescription and admission time: 1
    • active prescription and logistic regression: 1, 2
    • acute myocardial infarction and adjusted model: 1, 2, 3
    • acute myocardial infarction and admission prior: 1, 2, 3
    • acute myocardial infarction and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute myocardial infarction and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress and adjusted model: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory distress and admission confirm: 1
    • acute respiratory distress and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory distress and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress and admission ventilator: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory distress and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adjust analysis and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • adjust propensity score and admission time: 1
    • adjust propensity score and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8
    • adjusted model and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • adjusted model and admission ventilator: 1
    • adjusted model and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission prior and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25